CRMD stock icon

CorMedix
CRMD

$4.25
2.73%
 

About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Employees: 82

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 7 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

4% more capital invested

Capital invested by funds: $70.4M [Q4 2023] → $73.2M (+$2.82M) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

10% less funds holding

Funds holding: 100 [Q4 2023] → 90 (-10) [Q1 2024]

20.29% less ownership

Funds ownership: 51.7% [Q4 2023] → 31.41% (-20.29%) [Q1 2024]

32% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 34

56% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 18

68% less call options, than puts

Call options by funds: $394K | Put options by funds: $1.24M

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$9
112%
upside
Avg. target
$11.71
176%
upside
High target
$19
347%
upside

7 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Serge Belanger
135%upside
$10
Buy
Reiterated
19 Jun 2024
Needham
Serge Belanger
135%upside
$10
Buy
Reiterated
13 May 2024
JMP Securities
Jason Butler
347%upside
$19
Market Outperform
Reiterated
9 Apr 2024
Needham
Serge Belanger
135%upside
$10
Buy
Reiterated
9 Apr 2024
RBC Capital
Gregory Renza
112%upside
$9
Outperform
Maintained
13 Mar 2024

Financial journalist opinion